| (T-PLL) | T-cell prolymphocytic leukemia |
| AKT | serine/threonine-specific protein kinase |
| ALL | acute lymphoblastic leukemia |
| AML | acute myeloid leukemia |
| BiTE | bispecific T-cell engaging |
| B-NHL | B-cell non-Hodgkin lymphoma |
| CAR | chimeric antigen receptor |
| CLL | chronic lymphocytic leukemia |
| COVID 19 | coronavirus disease 2019 |
| CRES | CAR T-cell-related encephalopathy syndrome |
| CRP | C-reactive protein |
| CRS | cytokine release syndrome |
| CSF | colony-stimulating factor |
| DLBCL | diffuse Large B-cell Lymphoma |
| FDA | Food and Drug Administration |
| GCSF | granulocyte colony-stimulating factor |
| HGF | hepatocyte growth factor |
| HLH | haemophagocytic lymphohistiocytosis |
| HSCT | hematopoietic stem cell transplantation |
| ICU | intensive care unit |
| IFN | interferon |
| IL | interleukin |
| IL6R | IL6 Receptor |
| IP-10 | interferon–inducible protein 10 |
| JAK | Janus associated kinase |
| mAbs | monoclonal antibodies |
| MAPK | mitogen-activated protein kinase |
| MAS | macrophage activation syndrome |
| MCP | monocyte chemoattractant protein |
| MIP | macrophage inflammatory protein 1α |
| MSC | mesenchymal stem cells |
| NHL | non-Hodgkin lymphoma |
| NK | natural killer |
| PT | prothrombin time |
| PTT | partial thromboplastin time |
| SARS-CoV-2 | severe acute respiratory syndrome coronavirus 2 |
| sIL6R | soluble IL6 receptor |
| SS | Sézary syndrome |
| STAT | signal transducer and activator of transcription |
| TGF | transforming growth factors |
| TNF | tumor necrosis factors |